Lundbeck to seek new indication for Rexulti

Wednesday 17 August 2022


H. Lundbeck A/S and its Japanese partner Otsuka Pharmaceutical Co Ltd expect to make a regulatory filing for a new indication for Rexulti, an approved drug for schizophrenia and depression, before the end of the year. The proposed indication, for agitation in patients with Alzheimer’s dementia, would be supported by positive data from a Phase 3 study showing a statistically significant reduction in agitation in patients receiving the drug compared with placebo. The trial results were reported in June.